Cantor Fitzgerald Issues Positive Forecast for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of BioMarin Pharmaceutical in a research note issued to investors on Thursday, February 20th. Cantor Fitzgerald analyst O. Brayer now expects that the biotechnology company will post earnings per share of $3.53 for the year, up from their prior estimate of $3.09. Cantor Fitzgerald has a “Overweight” rating and a $90.00 price objective on the stock. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The business had revenue of $747.31 million for the quarter, compared to analysts’ expectations of $711.05 million.

Other research analysts have also issued reports about the company. Robert W. Baird cut their target price on BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. William Blair lowered BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 30th. Wedbush reaffirmed an “outperform” rating and issued a $94.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Piper Sandler increased their target price on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an “overweight” rating in a research report on Thursday, February 20th. Finally, Oppenheimer upgraded shares of BioMarin Pharmaceutical from a “market perform” rating to an “outperform” rating and set a $98.00 price target on the stock in a report on Monday. Seven research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $94.00.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $71.17 on Monday. BioMarin Pharmaceutical has a fifty-two week low of $60.63 and a fifty-two week high of $94.85. The firm’s 50 day moving average is $65.03 and its two-hundred day moving average is $70.48. The company has a market cap of $13.56 billion, a P/E ratio of 32.35, a P/E/G ratio of 0.61 and a beta of 0.28. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11.

Institutional Trading of BioMarin Pharmaceutical

Hedge funds have recently made changes to their positions in the stock. Merit Financial Group LLC bought a new position in BioMarin Pharmaceutical during the 4th quarter valued at $317,000. Assenagon Asset Management S.A. raised its stake in shares of BioMarin Pharmaceutical by 461.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company’s stock valued at $40,205,000 after purchasing an additional 502,695 shares in the last quarter. Wedmont Private Capital bought a new position in shares of BioMarin Pharmaceutical during the fourth quarter worth about $430,000. Swedbank AB lifted its position in shares of BioMarin Pharmaceutical by 11.2% during the fourth quarter. Swedbank AB now owns 432,122 shares of the biotechnology company’s stock worth $28,403,000 after purchasing an additional 43,593 shares during the last quarter. Finally, EULAV Asset Management grew its stake in BioMarin Pharmaceutical by 12.9% in the third quarter. EULAV Asset Management now owns 131,000 shares of the biotechnology company’s stock worth $9,208,000 after purchasing an additional 15,000 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Insider Activity at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,344 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $68.38, for a total transaction of $91,902.72. Following the sale, the chief accounting officer now directly owns 13,105 shares in the company, valued at $896,119.90. The trade was a 9.30 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.85% of the stock is currently owned by company insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.